Researchers presented early results from OCTANE, a U.S. real-world study examining what happens when patients switch from injectable GLP-1 therapy to the oral semaglutide tablet sold as Wegovy, at the EASD 2026 meeting in Milan. The study is one of the first to look specifically at the switching question now that a high-dose oral semaglutide tablet has FDA approval for weight management, rather than studying the pill only as a starting therapy on its own.
What OCTANE Looked At
The study followed adults who had been on injectable semaglutide or injectable tirzepatide and transitioned to the oral Wegovy tablet, tracking body weight over roughly three months after the switch. Because it's a real-world observational study rather than a randomized trial, patients and their doctors decided to make the switch for their own reasons, commonly needle aversion, side effects, insurance formulary changes, or simple preference, and researchers tracked what happened afterward rather than randomly assigning people to switch.
Why the Switching Question Matters
Injectable and oral GLP-1 drugs aren't absorbed the same way. The oral tablet requires a strict empty-stomach, limited-water dosing routine to achieve adequate absorption, which differs from an injectable's more forgiving pharmacokinetics. Whether someone maintains their weight-loss trajectory after switching from an injectable to the pill, or whether weight creeps back during the transition, is a practical question that has been largely unanswered outside of manufacturer-sponsored comparison trials. A three-month real-world readout is a first look, not a final answer.
Reading the Result Carefully
Because OCTANE's presented data is still early, limited to a three-month window, and observational rather than randomized, it shows an association rather than clean proof that switching itself causes any particular weight trend. People who choose to switch may differ in important ways, including insurance pressures or health status, from people who stay on an injectable, and a real-world study like this one can't fully rule out that kind of selection effect the way a randomized trial could. Longer follow-up, and ideally a randomized switching trial, would be needed to settle how durable the oral option is for someone transitioning from an injectable.
Regulatory and Access Context
The oral semaglutide tablet for weight management, discussed in more detail elsewhere on this site, received FDA approval as an addition to Novo Nordisk's Wegovy franchise alongside the long-available injectable version. Both the pill and the injectable remain prescription-only and require a doctor's involvement to start or switch between them.
The Bottom Line
OCTANE is a useful early signal for a question many patients are already raising with their doctors in practice, not a settled answer. Anyone considering switching between an injectable and oral GLP-1 medication should treat it as a decision to make with their prescribing physician, who can weigh their specific response to date, insurance situation, and tolerance for the pill's stricter dosing routine, rather than something to decide from a conference abstract alone.